Sec Form 4 Filing - Coulie Bernard @ PLIANT THERAPEUTICS, INC. - 2026-04-17

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Coulie Bernard 2. Issuer Name and Ticker or Trading Symbol PLIANT THERAPEUTICS, INC. [ PLRX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) President and CEO (Last) (First) (Middle) C/O PLIANT THERAPEUTICS, INC., 331 OYSTER POINT BOULEVARD 3. Date of Earliest Transaction (MM/DD/YY) 04/17/2026 (Street) SOUTH SAN FRANCISCO, CA94080 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 2.08 04/17/2026 D( 1 ) 146,841 ( 2 ) 01/24/2029( 3 ) Common Stock 146,841 $ 0 0 D Stock Option (Right to Buy) $ 1.33 ( 4 ) ( 5 ) 04/17/2026 A( 1 ) 146,841 ( 2 ) 01/24/2029( 3 ) Common Stock 146,841 $ 0 146,841 D Stock Option (Right to Buy) $ 6.22 04/17/2026 D( 1 ) 327,262 ( 2 ) 03/31/2030( 6 ) Common Stock 327,262 $ 0 0 D Stock Option (Right to Buy) $ 1.33 ( 4 ) ( 5 ) 04/17/2026 A( 1 ) 327,262 ( 2 ) 03/31/2030( 6 ) Common Stock 327,262 $ 0 327,262 D Stock Option (Right to Buy) $ 26.5 04/17/2026 D( 1 ) 250,000 ( 2 ) 01/23/2031( 7 ) Common Stock 250,000 $ 0 0 D Stock Option (Right to Buy) $ 1.33 ( 4 ) ( 5 ) 04/17/2026 A( 1 ) 250,000 ( 2 ) 01/23/2031( 7 ) Common Stock 250,000 $ 0 250,000 D Stock Option (Right to Buy) $ 11.86 04/17/2026 D( 1 ) 440,000 ( 2 ) 01/26/2032( 8 ) Common Stock 440,000 $ 0 0 D Stock Option (Right to Buy) $ 1.33 ( 4 ) ( 5 ) 04/17/2026 A( 1 ) 440,000 ( 2 ) 01/26/2032( 8 ) Common Stock 440,000 $ 0 440,000 D Stock Option (Right to Buy) $ 34.65 04/17/2026 D( 1 ) 206,300 ( 2 ) 01/25/2033( 9 ) Common Stock 206,300 $ 0 0 D Stock Option (Right to Buy) $ 1.33 ( 4 ) ( 5 ) 04/17/2026 A( 1 ) 206,300 ( 2 ) 01/25/2033( 9 ) Common Stock 206,300 $ 0 206,300 D Stock Option (Right to Buy) $ 17.44 04/17/2026 D( 1 ) 256,300 ( 2 ) 01/23/2034 Common Stock 256,300 $ 0 0 D Stock Option (Right to Buy) $ 1.33 ( 4 ) ( 5 ) 04/17/2026 A( 1 ) 256,300 ( 2 ) 01/23/2034 Common Stock 256,300 $ 0 256,300 D Stock Option (Right to Buy) $ 11.14 04/17/2026 D( 1 ) 325,000 ( 2 ) 01/23/2035 Common Stock 325,000 $ 0 0 D Stock Option (Right to Buy) $ 1.33 ( 4 ) ( 5 ) 04/17/2026 A( 1 ) 325,000 ( 2 ) 01/23/2035 Common Stock 325,000 $ 0 325,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Coulie Bernard C/O PLIANT THERAPEUTICS, INC. 331 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO, CA94080 X President and CEO Signatures /s/ Jennifer Woo, attorney-in-fact 04/17/2026 Signature of Reporting Person Date

Explanation of Responses:

( 1 )On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. ( 2 )The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates. ( 3 )The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from January 23, 2029 to the correct expiration date of January 24, 2029. ( 4 )The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). ( 5 )The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). ( 6 )The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from March 30, 2030 to the correct expiration date of March 31, 2030. ( 7 )The expiration date has been updated from the Form 4 originally filed on January 26, 2021 from January 22, 2031 to the correct expiration date of January 23, 2031. ( 8 )The expiration date has been updated from the Form 4 originally filed on February 2, 2022 from January 25, 2032 to the correct expiration date of January 26, 2032. ( 9 )The expiration date has been updated from the Form 4 originally filed on January 27, 2023 from January 24, 2033 to the correct expiration date of January 25, 2033.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.